-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US9013841070 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 266M |
|---|---|
| PE Ratio | None |
| Target Price | 5 |
| Beta | 1.05 |
| Dividend Yield | None |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TSVT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025